PMID: 9433383Jan 20, 1998Paper

Myeloid leukemia and myelodysplastic syndrome relapsing as granulocytic sarcoma (chloroma) after allogeneic bone marrow transplantation

Annals of Hematology
A SzomorA Gratwohl

Abstract

Of 229 consecutive patients receiving allogeneic blood or bone marrow stem cell transplants for acute myeloid leukemia, chronic myeloid leukemia, or myelodysplastic syndrome between 1974 and 1996, 52 patients relapsed. The original tumor recurred as granulocytic sarcoma (chloroma) in three patients (1.3%). Chloroma was found in the ovary in two patients and in the central nervous system in one patient. None of these three patients had experienced > or = grade II acute or more than limited chronic graft-versus-host disease. The intervals between transplantation and recurrence with chloroma were 2, 6, and 13 years. Two patients received a second transplant, and all three died of treatment sequelae.

Citations

Jul 2, 2004·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·J W LeeW I Yang
Oct 24, 2013·Radiation Oncology·Wan-Yu ChenAnn-Lii Cheng
Oct 27, 2006·Leukemia & Lymphoma·Isabel Cunningham
Dec 16, 2006·Leukemia & Lymphoma·Semra PaydasMelek Ergin
Oct 4, 2011·International Journal of Radiation Oncology, Biology, Physics·Richard BakstJoachim Yahalom
Sep 24, 2002·Hematology·Yesid AlvaradoFrancis J Giles
Apr 21, 2016·Blood Reviews·Melhem SolhAsad Bashey
Jan 5, 2011·Advances in Hematology·Richard BakstJoachim Yahalom
Jul 29, 2011·Blood·Richard L BakstJoachim Yahalom
Nov 15, 2003·International Journal of Surgical Pathology·J AudouinJ Diebold
Oct 1, 2011·Therapeutic Advances in Hematology·Batia Avni, Maya Koren-Michowitz
May 11, 2011·Journal of Korean Neurosurgical Society·Ki Seong Eom, Tae Young Kim
Mar 17, 2001·Nature Reviews. Genetics·J B Hagen
Mar 14, 2003·Nature·Mark S Boguski, Martin W McIntosh
Nov 19, 2010·Expert Review of Hematology·A John Barrett, Minoo Battiwalla
Jun 25, 2020·Current Oncology Reports·Richard BakstJoachim Yahalom
Dec 15, 2020·Critical Reviews in Oncology/hematology·Isabel Cunningham
Sep 3, 2005·Medicina clínica·Christelle Ferrà, Josep Castellví
Aug 13, 2021·Leukemia & Lymphoma·Hussein A AbbasTapan M Kadia

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.